Nasdaq: $25.89 (-0.35) | AIM: £3.77 (+0.07)
News & Presentations
Previous Article   |   Next Article
Other Ventures, RNS Announcements | 19 Apr 2010

Seven-year extension of IP protection for Chi-Med’s main prescription drug

1 items
a100419